AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ ...

The healthcare industry is a behemoth, with annual expenditures totaling $4.9 trillion in the United States alone. It's a ...

Despite the steep decline, ABBV’s ex-Humira platform grew more than 21% year over year (on a reported basis) in the first quarter of 2025, driven by its newer immunology drugs, Skyrizi and Rinvoq.

AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings, sending ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

How Quickly Will Skyrizi Work for Psoriatic Arthritis? If Skyrizi is working, your symptoms will start to improve over the first 1-2 months. Most people see the greatest improvements during the ...